TechneScan DTPA - Norvège - norvégien - Statens legemiddelverk

technescan dtpa -

curium netherlands b.v. - kalsiumtrinatriumpentetat - preparasjonssett til radioaktive legemidler

TechneScan HDP - Norvège - norvégien - Statens legemiddelverk

technescan hdp -

curium netherlands b.v. - natriumoksidronat - preparasjonssett til radioaktive legemidler

Ultra TechneKow FM - Norvège - norvégien - Statens legemiddelverk

ultra technekow fm -

curium netherlands b.v. - natriummolybdat mo-99 omdannet til natriumperteknetat tc-99m - radionuklidegenerator

Venticoll 0.5 mg Norvège - norvégien - Statens legemiddelverk

venticoll 0.5 mg

ge healthcare as - albumin, humant, kolloidale partikler - pulver til inhalasjonsvæske til nebulisator, oppløsning - 0.5 mg

Divifarm 800 IU Norvège - norvégien - Statens legemiddelverk

divifarm 800 iu

orifarm generics a/s - kolekalsiferol - tablett, filmdrasjert - 800 iu

Fulvestrant Medical Valley 250 mg Norvège - norvégien - Statens legemiddelverk

fulvestrant medical valley 250 mg

medical valley invest ab - fulvestrant - injeksjonsvæske, oppløsning i ferdigfylt sprøyte - 250 mg

Pemazyre Union européenne - norvégien - EMA (European Medicines Agency)

pemazyre

incyte biosciences distribution b.v. - pemigatinib - cholangiocarcinoma - antineoplastiske midler - pemazyre monotherapy is indicated for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that have progressed  after at least one prior line of systemic therapy.

Faslodex 250 mg/5 ml Norvège - norvégien - Statens legemiddelverk

faslodex 250 mg/5 ml

paranova as (1) - fulvestrant - injeksjonsvæske, oppløsning - 250 mg/5 ml

Fulvestrant SUN 250 mg Norvège - norvégien - Statens legemiddelverk

fulvestrant sun 250 mg

sun pharmaceutical - nederland - fulvestrant - injeksjonsvæske, oppløsning i ferdigfylt sprøyte - 250 mg

Rybrevant Union européenne - norvégien - EMA (European Medicines Agency)

rybrevant

janssen-cilag international n.v.    - amivantamab - karsinom, ikke-småcellet lunge - antineoplastiske midler - rybrevant as monotherapy is indicated for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating epidermal growth factor receptor (egfr) exon 20 insertion mutations, after failure of platinum-based chemotherapy.